{
  "pmcid": "11600501",
  "sha256": "ab87be56009cb76fdf4960f96c1098d8413149a3acca9476a15fa517603591f9",
  "timestamp_utc": "2025-11-09T15:21:22.944080+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.766398113675852,
    "reading_ease": 37.737549516008954,
    "word_count": 948
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "We included randomised controlled trials (RCTs) enrolling adults who underwent cardiac surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "prophylactically treated with one or multiple inotropic agent(s) in comparison to any type of control"
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the benefits and harms of the prophylactic use of any inotropic agent to prevent low cardiac output and associated morbidity and mortality in adults undergoing cardiac surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "levosimendan as compared to placebo may reduce the risk of LCOS (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.25 to 0.74; I 2 = 66%; 1724 participants, 6 studies; GRADE: low)"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "lack of blinding"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "We identified 29 eligible studies, including 3307 individuals"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "levosimendan as compared to placebo may reduce the risk of LCOS (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.25 to 0.74; I 2 = 66%; 1724 participants, 6 studies; GRADE: low)"
      },
      "Harms": {
        "score": 1,
        "evidence": "The risk of adverse events did not clearly differ between levosimendan and placebo groups"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}